Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cabaletta Bio Inc (NQ: CABA )

9.555 +0.535 (+5.93%)
Streaming Delayed Price Updated: 1:25 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 173,206
Open 9.020
Bid (Size) 9.510 (2)
Ask (Size) 9.590 (4)
Prev. Close 9.020
Today's Range 9.020 - 9.600
52wk Range 0.5900 - 13.44
Shares Outstanding 31,355,723
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 5/18
Via Investor Brand Network

Performance

YTD
+1.65%
+1.65%
1 Month
-16.18%
-16.18%
3 Month
+7.97%
+7.97%
6 Month
+169.15%
+169.15%
1 Year
+646.48%
+646.48%

More News

Read More
Cabaletta Bio Announces Pricing of Public Offering of Common Stock
From Cabaletta Bio
Via GlobeNewswire
Recap: Cabaletta Bio Q1 Earnings
Via Benzinga
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 5/2
Via Investor Brand Network
Where Cabaletta Bio Stands With Analysts
Via Benzinga
Where Cabaletta Bio Stands With Analysts
Via Benzinga
Cabaletta Bio Announces Proposed Public Offering of Common Stock
From Cabaletta Bio
Via GlobeNewswire
Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Stratasys, Navitas Semiconductor, United Insurance And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Receives FDA Fast Track Designation for CABA-201
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Cabaletta Bio
Via GlobeNewswire
Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus
From Cabaletta Bio
Via GlobeNewswire
Why Titan Machinery Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference
From Cabaletta Bio
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus’ Safety Switch System in Cell Therapies for Autoimmune Disease
From Autolus Therapeutics plc
Via GlobeNewswire
Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Cabaletta Bio
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.